11th Annual Drug Discovery For Neurodegeneration Conference

11th Annual Drug Discovery For Neurodegeneration Conference is organized by Alzheimers Drug Discovery Foundation (ADDF) and would be held during Feb 12 - 14, 2017 at DoubleTree By Hilton Hotel San Diego-Mission Valley, San Diego, California, United States of America.

The target audience for this medical event for Academic and industry scientists engaged in drug discovery research for neurodegenerative disease or CNS. Delegates at the Annual Drug Discovery for Neurodegeneration Conference are drawn from academia, industry, associations/societies, government and media.

This didactic conference will educate scientists on the processes of translating basic research into novel therapies and will leave participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug.

The programs will also highlight case studies of small molecule and biologics programs at different stages of development aimed at tackling challenging CNS targets relevant to neurodegenerative diseases.

Conference Objectives :
• Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease.
• Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease.
• Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease.
• Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.

WHAT WILL YOU LEARN? :
• Challenges and opportunities in academic drug discovery
• Fundamentals of medicinal chemistry relevant to drug discovery for neurodegenerative diseases
• Newest trends in assay development and high throughput screening (HTS)
• Go-no-go criteria for preclinical development, including pharmacokinetic behavior of candidate compounds, aqueous solubility, blood-brain barrier permeability, preliminary safety, and manufacturing issues
• Study design considerations for animal model experiments
• Biologics for challenging CNS targets and strategies to optimize brain delivery
• Requirements for an Investigational New Drug (IND) application
• Commercialization strategies for developing science into products
• Best practices for working with tech transfer offices, managing intellectual property, and the role of funding organizations
• Funding resources for preclinical therapeutics development for neurological disorders